← FDA DRUG APPROVALS

FDA ANDA · ANDA215527

DIVALPROEX SODIUM

Sponsor: ANNORA PHARMA

APPLICATION
ANDA215527
TYPE
ANDA
ORIGINAL APPROVAL
2023-09-26
LATEST ACTION
2025-04-15
ROUTE
ORAL
DOSAGE FORM
TABLET, EXTENDED RELEASE
MARKETING STATUS
Prescription

Products

DIVALPROEX SODIUMPrescription
DIVALPROEX SODIUM EQ 500MG VALPROIC ACID · TABLET, EXTENDED RELEASE · ORAL
DIVALPROEX SODIUMPrescription
DIVALPROEX SODIUM EQ 250MG VALPROIC ACID · TABLET, EXTENDED RELEASE · ORAL

Approval history

2025-04-15Labeling · Supplement 2 · standardAP
2024-08-29Labeling · Supplement 1 · standardAP
2023-09-26UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →